Experimental drug cocktail targets relapsed leukemia
NCT ID NCT04666649
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage trial tested a combination of two drugs, pegcrisantaspase and venetoclax, in 27 adults whose acute myeloid leukemia had come back or not responded to standard treatments. The main goal was to find safe doses and check for side effects. Researchers also looked at whether the treatment could lead to remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pegcrisantaspase and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong
This is a very early Phase 1 trial with only 27 participants, focused on safety and dosing. It may not lead to an effective treatment, and side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.